Alprazolam

Using ‘trip killers’ to cut short bad drug trips is potentially dangerous

Retrieved on: 
Wednesday, February 14, 2024

As interest in psychedelics has grown, so has interest in ways to end a bad trip.

Key Points: 
  • As interest in psychedelics has grown, so has interest in ways to end a bad trip.
  • Recent research reveals that people are giving potentially dangerous advice on social media on how to stop a trip that is less than pleasurable.
  • One of the earliest descriptions of a psychedelic experience in western literature can be found in Aldous Huxley’s 1953 book The Doors of Perception.
  • Research shows that if someone is in a bad mood or depressed then they are more likely to have a bad trip, as are people who take too high a dose.

Trip killers

  • Few clinical studies have examined trip killers, but one has found that ketanserin – a drug used to treat high blood pressure – reverses the psychedelic effects of LSD.
  • A recent article in the Emergency Medical Journal analysed posts on Reddit about trip killers.
  • Trip killers were discussed most often for LSD (235 posts), magic mushrooms (143 posts) and MDMA (21 posts).

Receptor blocking

  • To kill a trip then, one simply has to give the drug user another drug that blocks (rather than activates) the 5-HT2A receptor.
  • Many prescription drugs can do this and they tend to be antipsychotic drugs.
  • Quetiapine from the list above is one popular example, while another antipsychotic, olanzapine, was mentioned in 14 posts in that study.
  • Similarly, the atypical antidepressants trazodone and mirtazapine also block the 5-HT2A receptor.


Colin Davidson has previously received funding from the National Institute on Drug Abuse (NIH, USA) and the European Community for projects related to stimulant drug abuse and novel psychoactive compounds respectively. He is currently a paid consultant with the Defence Science Technology Laboratory (MOD) working on new psychoactive compounds.

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
Tuesday, November 14, 2023

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.

How drugs can warp your sense of time

Retrieved on: 
Thursday, August 10, 2023

Where trips to the dentist flew by in a second and holidays felt like they lasted forever.

Key Points: 
  • Where trips to the dentist flew by in a second and holidays felt like they lasted forever.
  • Time altering pills may sound like science fiction but the time warping effects of psychoactive drugs suggest that deliberate time manipulation may be possible.
  • Other drugs can scramble our sense of time completely.
  • Pregabalin, a drug used to treat epilepsy and anxiety, and anti-anxiety drug Xanax, both slow
    the passage of time.

So why do drugs warp time?

    • Drugs associated with increases in the passage of time are stimulants, which cause increased activity and excitation across the areas of the brain associated with cognitive function.
    • Drugs also affect behaviour and emotions, both of which can twist our experience of time.
    • Drugs such as cocaine and MDMA can have powerful effects on mood, inducing feelings of happiness and euphoria.
    • What you do while taking drugs will contribute to the sensation that time is bending.

The aftermath

    • The neurochemical, emotional and cognitive effects of comedowns create the perfect environment for time to drag.
    • The combination of exhaustion and low mood means that much of the recovery period is spent wondering “when will this end”, which also exaggerates the slowing of time.

Intertwined with human history and nature

    • They involve drinking a liquid brewed from leaves from the Psychotria viridis shrub and stalks of the Banisteriopsis caapi vine.
    • The brew causes changes in the state of consciousness, resulting in hallucinations and a significant change in the flow of time.
    • Nowadays, ayahuasca ceremonies attract tourists from across the world seeking to experience altered states of consciousness and spirituality.
    • Ruth Ogden receives funding from receives funding from The British Academy, The Wellcome Trust, The Economic and Social Research Council and CHANSE.

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Retrieved on: 
Monday, March 6, 2023

“Along these lines, we are excited to announce the updated clinical strategy for GRX-917.

Key Points: 
  • “Along these lines, we are excited to announce the updated clinical strategy for GRX-917.
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • The clinical development plan has been updated to now proceed with a phase 2 study in patients.
  • As part of a strategic review of its pipeline and to enhance operational efficiency and focus, the Company has reduced its workforce by approximately 30%.

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Retrieved on: 
Monday, January 9, 2023

GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.

Key Points: 
  • GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.
  • Initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
  • NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.
  • The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.

Chemical Planet Introduce A Sample Pack Of Its 10 Best Benzodiazepine Samples, Including Bromazolam, FANAX, And Fluetizolam, With A Total Of 90 Pellets

Retrieved on: 
Tuesday, November 29, 2022

Utrecht, Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chemical Planet is a progressive research chemical supply company that strives to become number 1 in the research chemical field.

Key Points: 
  • Utrecht, Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chemical Planet is a progressive research chemical supply company that strives to become number 1 in the research chemical field.
  • Benzodiazepines are a class of research chemicals that feature a fusion of a benzene ring with a diazepine ring.
  • A research chemical from the triazolobenzodiazepine family, Flubromazepam is a benzodiazepine derivative that provides similar effects to other benzodiazepine chemicals.
  • To find out more about Chemical Planet and to see a complete list of their Benzodiazepine experimental products, please visit their website at https://chemicalplanet.net/nl/ .

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Retrieved on: 
Tuesday, November 29, 2022

Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.

Key Points: 
  • Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.
  • Full details of the poster presentation are below:
    Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: We are pleased to present the design of this important ongoing study at the ESMO Asia congress.
  • Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice.
  • Available at: http://www.mascc.org/ /
    2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022.

Alprazolam (CAS 28981-97-7) Global Market Research Report 2022: Trends and Developments, Prices, Patents, Manufacturing Methods, Major Players, Applications, Key Downstream Industries - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 5, 2022

The "Alprazolam (CAS 28981-97-7) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alprazolam (CAS 28981-97-7) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Alprazolam.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Alprazolam global market report key points:

GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO

Retrieved on: 
Thursday, April 7, 2022

NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.

Key Points: 
  • NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.
  • GABA Therapeutics, an atai Life Sciences platform company, is a clinical stage biotechnology company focused on addressing the growing, unmet medical need in serious psychiatric and neurological disorders, including depression, anxiety, epilepsy, and essential tremor.
  • This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • All references in these Forward-Looking Statements to we, and our, refer to GABA and atai, as applicable.

Pushing DeFi to New Heights: Solanax Platform Goes Officially LIVE

Retrieved on: 
Thursday, March 3, 2022

Today, the team is immensely proud to announce itself - today marks the launch of the Solanax DEX, which is already live with swap and liquidity pool functionality enabled.

Key Points: 
  • Today, the team is immensely proud to announce itself - today marks the launch of the Solanax DEX, which is already live with swap and liquidity pool functionality enabled.
  • Being based on a permission-less, high-performance, Proof-of-History (PoH) blockchain, Solanax is able to ensure ample liquidity, minimal slippage, and offers support for market makers and trading bots.
  • The users will now be able to take advantage of lightning-fast trades, pooled liquidity, and additional features for generating revenue.
  • Solanax is a Solana-based automated market maker (AMM) exchange, providing lightning-fast trades, pooled liquidity, and other income-generating features.